Nurix Says First Patient Enrolled in Phase 1b/2 Lymphocytic Leukemia Combination Study

MT newswire2026/10/07 08:17

04:17 AM EDT, 10/07/2026 (MT Newswires) -- Nurix Therapeutics (NRIX) has enrolled the first patient in a phase 1b/2 study evaluating bexobrutideg for the treatment of certain blood cancers in a combination, the company said Wednesday. The investigational oral drug bexobrutideg will be used in combination with venetoclax, a standard-of-care therapy for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. The phase 1b/2 study is a global collaboration with the Swiss drugmaker Roche, to evaluate the safety, tolerability and clinical activity of bexobrutideg in combination with venetoclax, Nurix said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Updated version 2 - PepsiCo will cut some jobs in North America

路透社•2026/11/09 20:46

BUZZ-LifeStance Health shares rebound after sponsors sell $590 million worth of stock

路透社•2026/11/09 20:36

Sector Update: Financial Stocks Rise Late Afternoon

MT newswire•2026/11/09 20:04

Data: Arbitrum stablecoin DEX trading volume increased by $64.2 million in the past 7 days

Chaincatcher•2026/11/09 20:01